Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

GEORGE NEWMAN

NPI
1083616957
CMS profile
94689
Location
KNOXVILLE, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$164.33

9 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $164.33 9

By paying entity

PY2023 · entire year · sorted by reported total

Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

GEORGE NEWMAN

NPI 1083616957 · CMS profile ID 94689

KNOXVILLE, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1083616957?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
GEORGE NEWMAN, NPI 1083616957, CMS profile ID 94689. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1083616957?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). GEORGE NEWMAN, NPI 1083616957, CMS profile ID 94689. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1083616957?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
GEORGE NEWMAN, NPI 1083616957, CMS profile ID 94689, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1083616957?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

9 matching records · $164.33 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 9 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–9 of 9.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Kyowa Kirin, Inc. $20.7011/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026995867 CMS
Daiichi Sankyo Inc. $20.5711/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006540217 CMS
Novartis Pharmaceuticals Corporation $17.0710/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992951153 CMS
GlaxoSmithKline, LLC. $23.5610/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003031863 CMS
AstraZeneca Pharmaceuticals LP $25.6909/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025045517 CMS
Horizon Therapeutics plc $16.3909/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 987051675 CMS
Horizon Therapeutics plc $14.6307/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 987051673 CMS
Travere Therapeutics, Inc. $10.7906/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059564311 CMS
Horizon Therapeutics plc $14.9304/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 987051671 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2020 $178.30 6
PY2021 $377.67 24
PY2022 $417.29 17
PY2023 $164.33 9
PY2024 $155.60 9
PY2025 $74.00 4

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $182,880.78 51
PY2024 Principal investigator $87,718.55 35
PY2023 Principal investigator $222,950.49 61
PY2022 Principal investigator $86,493.52 23
PY2021 Principal investigator $51,212.91 4
PY2020 Principal investigator $7,179.73 10
PY2019 Principal investigator $42,450.56 43

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

51 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 CSL Behring $8,815.00 12/29/2025 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252675694
Principal investigator 1 CSL Behring $750.00 12/05/2025 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252676014
Principal investigator 1 CSL Behring $750.00 12/05/2025 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252676016
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,283.86 11/24/2025 Non-covered Recipient Entity
Kkc Research Group Llc
A randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase 3 study to investigate the efficacy and safety of FInerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic K No dispute reported 06/30/2026 1225415338
Principal investigator 1 CSL Behring $2,647.00 11/17/2025 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252676162
Principal investigator 1 CSL Behring $282.30 11/14/2025 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252674362
Principal investigator 1 CSL Behring $14,330.00 10/29/2025 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252676068
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,141.06 10/28/2025 Non-covered Recipient Entity
Kkc Research Group Llc
A randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase 3 study to investigate the efficacy and safety of FInerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic K No dispute reported 06/30/2026 1225414020
Principal investigator 1 CSL Behring $411.40 10/27/2025 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252674614
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,572.51 09/25/2025 Non-covered Recipient Entity
Kkc Research Group Llc
A randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase 3 study to investigate the efficacy and safety of FInerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic K No dispute reported 06/30/2026 1225414520
Principal investigator 1 CSL Behring $5,289.00 09/17/2025 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252676630
Principal investigator 1 CSL Behring $112.41 09/11/2025 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252674498
Principal investigator 1 CSL Behring $7,578.00 08/20/2025 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252676482
Principal investigator 1 CSL Behring $70.26 08/19/2025 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252674736
Principal investigator 1 CSL Behring $77.83 08/19/2025 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252674738
Principal investigator 1 CSL Behring $16.71 08/04/2025 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252674798
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,070.53 07/24/2025 Non-covered Recipient Entity
Kkc Research Group Llc
A randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase 3 study to investigate the efficacy and safety of FInerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic K No dispute reported 06/30/2026 1225413156
Principal investigator 1 CSL Behring $1,270.46 07/16/2025 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252675008
Principal investigator 1 CSL Behring $10,117.00 07/16/2025 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252676724
Principal investigator 1 CSL Behring $200.00 07/11/2025 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252676698
Principal investigator 1 CSL Behring $1,000.00 07/11/2025 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252676700
Principal investigator 1 CSL Behring $1,500.00 07/11/2025 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252676702
Principal investigator 1 CSL Behring $2,000.00 07/11/2025 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252676704
Principal investigator 1 CSL Behring $8,800.00 07/11/2025 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252676706
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $4,216.80 07/03/2025 Non-covered Recipient Entity
Kkc Research Group Llc
A randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase 3 study to investigate the efficacy and safety of FInerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic K No dispute reported 06/30/2026 1225413104
Principal investigator 1 CSL Behring $48.75 07/03/2025 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252674974
Principal investigator 1 CSL Behring $3,526.00 06/30/2025 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252676914
Principal investigator 1 CSL Behring $363.23 06/11/2025 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252674904
Principal investigator 1 CSL Behring $4,410.00 06/06/2025 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252677138
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,561.66 05/30/2025 Non-covered Recipient Entity
Kkc Research Group Llc
A randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase 3 study to investigate the efficacy and safety of FInerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic K No dispute reported 06/30/2026 1225412644
Principal investigator 1 CSL Behring $500.00 05/28/2025 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252677164
Principal investigator 1 CSL Behring $6,298.00 05/14/2025 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252677044
Principal investigator 1 CSL Behring $263.32 05/08/2025 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252675166
Principal investigator 1 CSL Behring $355.20 05/06/2025 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252675150
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,128.60 05/05/2025 Non-covered Recipient Entity
Kkc Research Group Llc
A randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase 3 study to investigate the efficacy and safety of FInerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic K No dispute reported 06/30/2026 1225412606
Principal investigator 1 CSL Behring $5,289.00 04/16/2025 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252677330
Principal investigator 1 CSL Behring $16.71 04/08/2025 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252675392
Principal investigator 1 CSL Behring $190.25 04/01/2025 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252675324
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,482.48 03/27/2025 Non-covered Recipient Entity
Kkc Research Group Llc
BAY 948862, A randomised, double-blind, placebo-controlled, parallel-group, multicentre Phase 3 study to investigate the efficacy and safety of Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic No dispute reported 06/30/2026 1225402635
Principal investigator 1 CSL Behring $363.23 03/27/2025 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252675316
Principal investigator 1 CSL Behring $123.23 03/20/2025 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252675258
Principal investigator 1 CSL Behring $7,278.00 03/19/2025 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252677556
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $32,835.70 03/12/2025 Non-covered Recipient Entity
KNOXVILLE KIDNEY CENTER PLLC
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Povetacicept in Adults With Immunoglobulin A Nephropathy (RAINIER) No dispute reported 06/30/2026 1214124590
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $8,566.99 03/06/2025 Non-covered Recipient Entity
Kkc Research Group Llc
BAY 948862, A randomised, double-blind, placebo-controlled, parallel-group, multicentre Phase 3 study to investigate the efficacy and safety of Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic No dispute reported 06/30/2026 1225405388
Principal investigator 1 CSL Behring $544.25 02/21/2025 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252675636
Principal investigator 1 CSL Behring $5,515.00 02/19/2025 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252677460
Principal investigator 1 CSL Behring $198.92 02/04/2025 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252675828
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,409.32 01/28/2025 Non-covered Recipient Entity
Kkc Research Group Llc
BAY 948862, A randomised, double-blind, placebo-controlled, parallel-group, multicentre Phase 3 study to investigate the efficacy and safety of Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic No dispute reported 06/30/2026 1225403791
Principal investigator 1 Novartis Pharmaceuticals Corporation $19,648.12 01/17/2025 Non-covered Recipient Entity
KNOXVILLE KIDNEY CENTER PLLC
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of BION-1301 in Adults With IgA Nephropathy (The BEYOND Study) No dispute reported 06/30/2026 1190313085
Principal investigator 1 CSL Behring $360.00 01/10/2025 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252677710
Principal investigator 1 CSL Behring $302.69 01/09/2025 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252675788